These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
114 related articles for article (PubMed ID: 15297045)
21. Vacc-4x, a therapeutic vaccine comprised of four engineered peptides for the potential treatment of HIV infection. Jones T Curr Opin Investig Drugs; 2010 Aug; 11(8):964-70. PubMed ID: 20721838 [TBL] [Abstract][Full Text] [Related]
23. Induction of potent CD8+ T-cell responses by novel biodegradable nanoparticles carrying human immunodeficiency virus type 1 gp120. Wang X; Uto T; Akagi T; Akashi M; Baba M J Virol; 2007 Sep; 81(18):10009-16. PubMed ID: 17609261 [TBL] [Abstract][Full Text] [Related]
24. Therapeutic vaccination against HIV: current progress and future possibilities. Puls RL; Emery S Clin Sci (Lond); 2006 Jan; 110(1):59-71. PubMed ID: 16336205 [TBL] [Abstract][Full Text] [Related]
25. FDA advisory committees meet January 26 on Salk HIV-1 immunogen. AIDS Treat News; 1995 Jan; (No 214):1-2. PubMed ID: 11362184 [TBL] [Abstract][Full Text] [Related]
26. Therapeutic dendritic-cell vaccine for chronic HIV-1 infection. Lu W; Arraes LC; Ferreira WT; Andrieu JM Nat Med; 2004 Dec; 10(12):1359-65. PubMed ID: 15568033 [TBL] [Abstract][Full Text] [Related]
27. Restoring HIV-specific immunity. James JS AIDS Treat News; 1999 Feb; (No 312):2-6. PubMed ID: 11366200 [TBL] [Abstract][Full Text] [Related]
28. Distinct mechanisms for mitochondrial DNA loss in T and B lymphocytes from HIV-infected patients exposed to nucleoside reverse-transcriptase inhibitors and those naive to antiretroviral treatment. Maagaard A; Holberg-Petersen M; Løvgården G; Holm M; Pettersen FO; Kvale D J Infect Dis; 2008 Nov; 198(10):1474-81. PubMed ID: 18851688 [TBL] [Abstract][Full Text] [Related]
29. Enhancement of HIV type 1 antigen-specific CD4+ T cell memory in subjects with chronic HIV type 1 infection receiving an HIV type 1 immunogen. Maino VC; Suni MA; Wormsley SB; Carlo DJ; Wallace MR; Moss RB AIDS Res Hum Retroviruses; 2000 Apr; 16(6):539-47. PubMed ID: 10777144 [TBL] [Abstract][Full Text] [Related]
30. Maternal 12-month response to antiretroviral therapy following prevention of mother-to-child transmission of HIV type 1, Ivory Coast, 2003-2006. Coffie PA; Ekouevi DK; Chaix ML; Tonwe-Gold B; Clarisse AB; Becquet R; Viho I; N'dri-Yoman T; Leroy V; Abrams EJ; Rouzioux C; Dabis F Clin Infect Dis; 2008 Feb; 46(4):611-21. PubMed ID: 18197758 [TBL] [Abstract][Full Text] [Related]
31. Phase II placebo-controlled study of V-1 Immunitor as a therapeutic modality for treatment of HIV. Bourinbaiar AS; Jirathitikal V; Metadilogkul O; Sooksathan P; Paiboon P; Aemsri S; Prapai P; Chaodon K J Clin Virol; 2004 Dec; 31 Suppl 1():S55-62. PubMed ID: 15567095 [TBL] [Abstract][Full Text] [Related]
32. Effect of immunization with inactivated gp120-depleted human immunodeficiency virus type 1 (HIV-1) immunogen on HIV-1 immunity, viral DNA, and percentage of CD4 cells. Trauger RJ; Ferre F; Daigle AE; Jensen FC; Moss RB; Mueller SH; Richieri SP; Slade HB; Carlo DJ J Infect Dis; 1994 Jun; 169(6):1256-64. PubMed ID: 7910836 [TBL] [Abstract][Full Text] [Related]
33. Improving immune function and controlling viral replication in HIV-1-infected patients with immune-based therapies. Angel JB AIDS Read; 2001 Apr; 11(4):209-21. PubMed ID: 11392678 [TBL] [Abstract][Full Text] [Related]
34. Induction of dendritic cell-mediated immune responses against HIV-1 by antigen-capturing nanospheres in mice. Kawamura M; Wang X; Uto T; Sato K; Ueno M; Akagi T; Hiraishi K; Matsuyama T; Akashi M; Baba M J Med Virol; 2005 May; 76(1):7-15. PubMed ID: 15778965 [TBL] [Abstract][Full Text] [Related]